Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Effectiveness of Novel Therapies for Cutaneous SLE Explored

  |  Issue: April 2017  |  

Thomas R. Collins is a freelance writer living in South Florida.

References

  1. Furie R, Werth V, Merola J, et al. BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof on concept in subjects with active cutaneous SLE [abstract 2013]. Arthritis Rheumatol. 2016;68(suppl 10).
  2. Costedoat-Chalumeau N, Houssiau F, Izmirly P, et al. Predictive factors of adherence to treatment in an international prospective study of blood hydroxychloroquine levels in SLE patients with flares [abstract 2010]. Arthritis Rheumatol. 2016;68(suppl 10).
  3. Merrill J, Furie R, Werth V, et al. The effect of anifrolumab on cutaneous manifestations and arthritis in moderate to severe systemic lupus erythematosus (SLE) using categorical SLEDAI-2K responses and continuous measures of activity as outcome measures [abstract 2009]. Arthritis Rheumatol. 2016;68(suppl 10).

Related Articles

    Reading Rheum

    Handpicked Reviews of Contemporary Literature

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?

    The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…

    New Study Probes Hydroxychloroquine Adherence During Pregnancy

    Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…